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While oxidant stress is elevated in adult forms of pulmonary hypertension (PH), levels of oxidant stress in pediatric PH are
unknown. The objective of this study is to measure F2-isoprostanes, a marker of oxidant stress, in children with idiopathic
pulmonary hypertension (IPH) and PH due to bronchopulmonary dysplasia (BPD). We hypothesized that F2-isoprostanes in
pediatric IPH and PH associated with BPD will be higher than in controls. Plasma F2-isoprostanes were measured in pediatric
PH patients during clinically indicated cardiac catheterization and compared with controls. F2-Isoprostane levels were compared
between IPH, PH due to BD, and controls. Five patients with IPH, 12 with PH due to BPD, and 20 control subjects were studied.
Patients with IPH had statistically higher isoprostanes than controls 62 pg/mL (37–210) versus 20 pg/mL (16–27), P < 0.01). The
patients with PH and BPD had significantly lower isoprostanes than controls 15 pg/ml (8–17) versus 20 pg/mL (16–27), P < 0.02.
F2-isoprostanes are elevated in children with IPH compared to both controls and patients with PH secondary to BPD. Furthermore,
F2-isoprostanes in PH secondary to BPD are lower than control levels. These findings suggest that IPH and PH secondary to BPD
have distinct mechanisms of disease pathogenesis.
1. Introduction
It has long been recognized that patients with pediatric
idiopathic pulmonary hypertension (IPH) have poor long-
term survival. More recently pulmonary hypertension (PH)
associated with bronchopulmonary dysplasia (BPD) has
been identified as a significant cause ofmortality among BPD
patients [1, 2]. Few studies have evaluated the mechanisms
and optimal treatment of PH due to BPD, resulting in
management strategies for these patients which mirror the
better studied pharmacologic treatments of IPH. The use of
similar therapeutic strategies in these two populations relies
on the unproven assumption that the diseases share similar
molecular pathophysiologies.
Oxidant stress appears to play a role in the molecular
mechanism of adult IPH. Multiple studies measuring F2-
isoprostanes, a stable marker of oxidant stress resulting
from the oxidation of cell-membrane arachidonic acid, have
shown adult IPH patients, have higher F2-isoprostane levels
than do control patients [3, 4]. Elevated F2-isoprostane
levels suggest enhanced oxidant stress in IPH patients and
may also directly contribute to pulmonary vasoconstriction
[5]. There are no published data on oxidant stress or F2-
isoprostane levels in pediatric patients with PH secondary to
BPD or IPH. The objective of this study is to measure F2-
isoprostanes in children with IPH and PH due to BPD and to
compare them to normal controls to assess the role of oxidant
stress in pediatric populations with PH. We hypothesize
that children with IPH and PH due to BPD will have F2-
isoprostane levels higher than those measured in healthy
control subjects. Evidence supporting similar biochemical
mechanisms between these pediatric populations with PH
would support the practice of utilizing similar therapeutic
strategies in these children.
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2. Materials and Methods
2.1. Study Population. All patients who presented to the
pediatric catheterization laboratory at Vanderbilt Children’s
Hospital for evaluation of pulmonary hypertension between
December 2007 and December 2008 were approached for
participation in the study. Patients were excluded if they had
ventricular septal defects; patients with an atrial septal defect
or hemodynamically insignificant patent ductus arteriosus
were allowed. Other exclusion criteria were pulmonary vein
stenosis, valvar stenosis of any kind, aortic arch obstruction,
left ventricular dysfunction, active infection of any kind, and
autoimmune disease. All catheterizations were performed for
clinical reasons in accordance with the standard of care at the
Vanderbilt Pulmonary Hypertension Center.
Two groups of control patients were enrolled. The pri-
mary control group was recruited from the general pediatric
clinic at Vanderbilt Children’s Hospital. Patients without
acute or chronic illness who required a routine blood draw
for health maintenance were approached for enrollment
in the study. In addition, in order to assess the effect of
general anesthesia and the general impact of the catheter-
ization on F2-isoprostane levels, patients presenting to the
pediatric catheterization laboratory for atrial septal defect
(ASD) device closure were also approached to participate
as controls. Patients undergoing device ASD closure were
chosen because they typically do not have elevation of their
pulmonary artery pressure and are in good general health.
Exclusion criteria for both control groups were a history
of prematurity, ventricular septal defect, pulmonary vein
stenosis, valvar stenosis of any kind, aortic arch obstruction,
left ventricular dysfunction, active infection of any kind, and
autoimmune disease.
2.2. Echocardiography. All consenting control subjects re-
cruited from the general pediatric clinic underwent echocar-
diography to screen for undiagnosed pulmonary hyperten-
sion. Right ventricular pressure was assessed by interrogation
of the tricuspid regurgitation jet and utilization of the
Bernoulli equation. The right atrial pressure was assumed to
be 5mmHg. Any right ventricular pressure measurement of
greater than 30mmHg was deemed elevated. In the absence
of tricuspid regurgitation, flattening of the ventricular
septum during systole in the parasternal short axis was
defined as evidence of elevated right ventricular pressure.
The echocardiograms were independently reviewed by two
pediatric cardiologists. Evidence of elevated right ventricular
pressure found by one or more reviewer excluded a patient
from participation as a control subject.
2.3. Cardiac Catheterization. At the Vanderbilt Pediatric
Pulmonary Hypertension Center, the timing of cardiac
catheterization is specific to each type of PH. IPH patients
undergo cardiac catheterization with vasodilatory testing at
diagnosis and every 3–12 months thereafter depending on
their clinical status and changes in therapy. Patients with
PH and BPD are not routinely catheterized at diagnosis
unless structural abnormalities are suspected such as pul-
monary vein stenosis. Our center uses echocardiography
to identify and follow elevated pulmonary artery pressure
in neonates with BPD in the neonatal ICU and in follow
up after discharge from the ICU. Tricuspid regurgitation
velocity and systolic flattening of the ventricular septum
are the primary echocardiographic features used to assess
pulmonary artery pressure. BPD patients with persistent
echocardiographic evidence of elevated pulmonary artery
pressure are followed in the PH clinic as outpatients and
undergo catheterization within 3–6 months if on vasodilator
therapy. BPD-PH patients may also undergo catheterization
prior to discontinuation of vasodilator therapy.
Consenting participants with PH and the ASD con-
trol patients underwent their clinically indicated cardiac
catheterization under general anesthesia. All patients under-
went a right heart catheterization with directly measured
saturations and pressures at the lowest FiO2 were required to
maintain oxygen saturations of above 95% by pulse oximetry.
In patients with an ASD, a catheter was placed across the ASD
from the right heart to obtain a pressure in the left atrium
and a saturation measurement from a pulmonary vein. A
femoral artery sheath was placed in all patients to directly
measure the systemic blood pressure and the descending
aortic saturation. Pulmonary flows were calculated using the
Fick equation with assumed oxygen consumption in all BPD
patients, in the IPH patients with an atrial septal defect,
and in all the ASD control patients. Thermodilution was
used to measure pulmonary flow in IPH patients without
an atrial septal defect. All pulmonary flows were indexed to
body surface area. Pulmonary vascular resistance (PVR) was
calculated inWoods units (WU) and indexed to body surface
area.
2.4. Blood Sampling. In control patients recruited from the
general pediatric clinic, 5mLs of study blood was drawn by
routine phlebotomy. ASD control patients and PH patients
had 5mls of study blood drawn during the baseline hemody-
namic measurements. If patients undergoing catheterization
had a pulmonary venous sample obtained, the study blood
was taken from a pulmonary vein. Catheterized patients
without an ASD had study blood obtained in the descending
aorta through the femoral arterial sheath or arterial catheter.
All blood samples were obtained before any pulmonary
vasodilator testing was performed. All study blood was col-
lected on ice in an EDTA tube and immediately transported
to the laboratory for isoprostane analysis.
2.5. F2-Isoprostane Analysis. F2-isoprostanes were measured
using a method pioneered by Drs. Morrow and Roberts [6].
Briefly this involves passing the sample through two Waters
Corporation Sep-Pak cartridges to remove much of the
unwanted impurities. First one uses a C-18 packing material
and the second uses a silica packing material. The final
elution is then esterified with pentafluorobenzyl bromide
and silated with bis(trimethylsilyl)trifluoroacetamide before
being subjected to GC/MS analysis on an Agilent 5973 inert
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Table 1: Subjects’ demographics.
Control IPH PH due to BPD P value
N 18 4 12
Age§ (years) 7.5 (3.8–15.3) 11 (3–16.8) 2 (1–2.8) <.01∗
Gender (# male) 10 2 10 .63∗∗, .12†, .25¶
BMI§ (kg/m2) 17.9 (16.6–25.2) 23.1 (15.4–27.1) 16.1 (15.7–16.7) .02∗
Race (# Caucasian) 10 4 8 .14∗∗, .41†, .27¶
∗
P value based on the Kruskal-Wallis test.
∗∗P value based on the Fisher’s exact test of control versus IPH.
†P value based on the Fisher’s exact test of control versus PH due to BPD.
¶P value based on the Fisher’s exact test of IPH versus PH due to BPD.
§Data expressed as median (IQR).
MSD coupled with and Agilent 6890N Network GC from
Agilent Technologies in Wilmington, Delaware.
2.6. Statistical Analysis. Study data were collected and man-
aged using the REDCap electronic data capture tools hosted
at Vanderbilt University [7]. Data are presented as medians
with interquartile ranges (IQR) due to lack of normal
distribution. The Mann-Whitney U test was performed
to determine the statistical significance of the difference
between any two groups. The Kruskal-Wallis test was used
to analyze differences between all three groups. Categorical
variables between groups were assessed with the Fisher’s
exact test. Spearman’s test was used to analyze correlations. A
two-tailed α of <0.05 was considered statistically significant.
Bonferroni correction was not used due to its conservative
nature and the small number of comparisons done in this
study. SPSS was used to perform the statistical analysis (IBM
SPSS statistics, version 20).
This study was approved by the Institutional Review
Board of the Vanderbilt University Medical Center.
3. Results
We enrolled 5 patients with IPH and 12 patients with PH
secondary to BPD. All PH patients approached consented to
participate in the study. Twenty controls, including 5ASD
patients and 15 healthy controls from the primary care
clinic, consented to participate in the study. Three eligible
control patients approached in the primary care clinic
refused to participate because they did not have time to
undergo echocardiography. All ASD patients approached to
participate consented. None of the healthy control subjects
had abnormal echocardiograms. One of the 5 IPH patients
underwent diagnostic catheterization while the remainder
underwent routine follow-up catheterizations. All of the
BPD patients were catheterized for purposes of treatment
follow-up. The F2-isoprostane data could not be obtained in
one IPH patient and two controls due to sample problems.
Table 1 describes the baseline characteristics of the
study groups. The median age of control patients did not
statistically differ from IPH patients (P = 0.99), but those
with PH due to BPDwere significantly younger than controls
(P < 0.01). There was no statistical difference in gender
distribution between the controls and the two PH groups.
Table 2: Medical therapy of pulmonary hypertension patients.
IPH PH due to BPD P value
N 4 12
Home 1 8 .13∗
Oxygen
(No. of patients)
Epoprostenol 3 2 .06∗
(No. of patients)
Bosentan 1 1 .52∗
(No. of patients)
Sildenafil 3 11 .45∗
(No. of patients)
Months on 17.5 (4–27.5) 20 (12–29) .99∗∗
Therapy†
∗P value based on Fisher’s exact test.
∗∗P values based on Mann-Whitney U test.
†Data expressed as median (IQR).
While the body mass index (BMI) of the IPH patients did
not significantly differ from the controls, the BMI of those
with PH due to BPD was significantly less than controls
(P = 0.01).
Themedical treatments of patients with PH are described
in Table 2. There were significantly more IPH patients
treated with epoprostenol than patients with PH due to
BPD, although this did not reach statistical significance (P =
0.06). There was no difference in the number of subjects on
bosentan, sildenafil, and home oxygen in the two PH groups.
The hemodynamic data from the cardiac catheterizations
are presented in Table 3. The control patients undergoing
ASD device closure had normal right ventricular pressure
and pulmonary vascular resistance which were significantly
lower than in both the IPH group (P < 0.01) and the
BPD-PH group (P < 0.01). The right and left ventricular
end diastolic pressures, cardiac index, and baseline FiO2
in ASD controls were not different from either PH group.
As expected, those undergoing ASD device closure had a
larger pulmonary to systemic blood flow ratio than those
with IPH (P < 0.01) and PH due to BPD (P < 0.01).
The median right ventricular pressure as a percentage of
left ventricular pressure (RVP/LVP ratio) and the median
PVR were distinctly lower in those with PH due to BPD
4 Pulmonary Medicine
Table 3: Hemodynamics of subjects in catheterization laboratory¶.
IPH PH due to BPD ASD controls
P value
IPH versus BPD
N 4 12 5
RVP/LVP (%) 83 (80–1.1) 46 (38–59) .24 (.22–.25) .08∗
Pulmonary vascular resistance (WUs)† 17.2 (16.2–19.6) 4 (3.5–5.4) 1.4 (1.1–1.6) .08∗
Mean PAP†† (mmHg) 61 (53–63) 25 (22–36) 17 (14–19) .08∗
RVEDP‡ (mmHg) 10 (8–10) 7.5 (6.3–9) 8 (7.5–8.5) .26∗
LVEDP6 (mmHg) 8 (8–9) 8 (7–9) 10 (8–10) .99∗
Cardiac index (L/min/m2) 3.6 (3.1–3.6) 3.6 (3.5–3.8) 3.0 (2.7–3.5) .99∗
Qp :Qs§ .87 (0.8-.94) 1.0 (1.0-1.0) 2.1 (1.6–4.1) .53∗
Baseline FiO2(%) 21 (21–26) 21 (21-22) 21 (21–21) .52∗
ASD (# patients) 2 7 5 .62∗∗
∗
Value based on Mann-Whitney U test.
∗∗Value based on Fisher’s exact test.
†Indexed to body surface area.
††Pulmonary artery pressure.
‡Right ventricular end diastolic pressure.
‡‡Left ventricular end diastolic pressure.
§Ratio of pulmonary to systemic blood flow.
¶Interval data expressed as median (IQR).
compared to those with IPH, but the differences did not quite
reach statistical significance. The median right ventricular
end diastolic pressure (RVEDP), left ventricular end diastolic
pressure (LVEDP), and baseline FiO2 were not significantly
different among the two groups with PH. A patent foramen
ovale was found in 5 patients with PH secondary to BPD,
and a moderate atrial septal defect was found in one patient
with PH secondary to BPD. One patient with PH secondary
to BPD had a patent foramen ovale in addition to a small
patent ductus arteriosus. In those with IPH, two patients had
small atrial septal defects.
Patients with IPH had significantly higher F2-isopros-
tanes than controls (62 pg/mL (37–210) versus 20 pg/mL
(16–27), P ≤ 0.01) (Figure 1) . The patients with PH due to
BPD had significantly lower F2- isoprostanes than controls
(15 pg/mL (8–17) versus 20 pg/mL (16–27), P = 0.02). F2-
Isoprostane levels in IPH patients were significantly higher
than those with PH secondary to BPD (P = 0.002). No
correlation was found between F2-isoprostane levels and
age (R2S = 0.02) or between F2-isoprostane levels and
BMI (R2S = 0.09) in the study cohort. Among all PH
patients, no correlation was found between F2-isoprostanes
and RVP/LVP ratio (R2S = 0.02) or any other hemodynamic
measure. When analyzing only BPD patients with RVP/LVP
>50%, those with PH due to BPD still had lower F2-
isoprostanes ((8.7 pg/mL (6.3–12.7)) than controls (P ≤
0.01) and those with IPH (P = 0.02). No significant
difference was found between the F2-isoprostane levels of the
control subjects undergoing ASD device closure and those
undergoing routine phlebotomy (P = 0.95). Similarly, the
F2-isoprostanes drawn from the pulmonary veins were not
significantly different from those drawn from the descending
aorta among those with PH due to BPD (P = 0.09) or among
those with IPH (P = 0.44).


















Figure 1: Box plot of plasma F2-isoprostanes in IPH, PH due
to BPD, and controls. F2-Isoprostanes are significantly higher in
children with IPH compared to pediatric controls and children with
PH secondary to BPD. Plasma F2-isoprostanes are statistically lower
in children with PH secondary to BPD compared to those with IPH
and pediatric controls.
Both the IPH and BPD-PH groups had one outlier with
a high F2-isoprostane level. The BPD patient with the high
isoprostane value had only mildly elevated pulmonary artery
pressures with a RVP/LVP ratio of .38 and a PVR of 3.6
WU and was only being treated with sildenafil and home
oxygen. The IPH patient with the high isoprostane value
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had similar hemodynamics to the other IPH patients with
a RVP/LVP ratio of .83, a PVR of 17.1 WU, a RVEDP of
10mmHg, and a LVEDP of 10mmHg. This IPH patient was
on epoprostenol and sildenafil similar to the remaining IPH
patients but was the only one on bosentan. When repeating
the analysis without the two outlier, the F2-isoprostanes of
the IPH group are still significantly higher than the BPD-PH
group (P = 0.01), and the control F2-isoprostanes are still
significantly lower than the IPH group (P = 0.02) and higher
than the BPD-PH group (P < 0.01).
4. Discussion
F2-isoprostanes are elevated in pediatric patients with IPH
but not in those with PH secondary to BPD. In fact,
F2-isoprostanes in the BPD-PH group seem to be lower
than controls. Anesthesia and the general effect of the
catheterization did not appear to influence F2-isoprostane
levels as there was no difference between the ASD controls
and the clinic controls. To our knowledge, this is the first time
F2-isoprostane levels have been studied in pediatric patients
with IPH and PH secondary to BPD. Different F2-isoprostane
levels suggest that IPH and PH secondary to BPD have
distinct molecular pathophysiologies with different degrees
of chronic oxidant injury. This suggests that these entities
may be amenable to different pharmacologic approaches.
The finding of elevated F2-isoprostanes in children with IPH
is consistent with the elevated levels previously reported in
the adult populations with IPH [3]. F2-isoprostanes have
been shown to have a direct role in producing pulmonary
vasoconstriction by the activation of thromboxane receptors
and increasing the production of potent vasoconstrictors
such as thromboxane A2 and endothelin 1 [3, 8]. Our finding
of elevated circulating F2-isoprostane levels in pediatric
patients with IPH suggests enhanced oxidant stress in
these patients which may directly contribute to pulmonary
vasoconstriction.
The low levels of F2-isoprostanes in PH secondary to
BPD was an unexpected finding. Two groups have previously
shown elevated levels of F2-isoprostanes in premature infants
in the first weeks of life [9, 10]. Impaired and disordered
angiogenesis and resultant impaired alveolarization due at
least in part to oxidant damage is thought to underlie much
of the BPD phenotype [11]. The natural history of oxidant
stress in premature infants with or without PH due to BPD
is unknown. In this study, there was no difference in months
on treatment between the IPH group and the BPD-PH group
suggesting the two cohorts are at reasonably similar points
in disease time course. Even if the F2-isoprostane levels are
elevated early in the course of PH secondary to BPD, the
low levels we found in these established BPD-PH patients is
in marked contrast to the elevated levels we found in IPH
patients at a similar point in disease course.
The etiology of low levels of F2-isoprostanes in children
with PH secondary to BPD is unknown. F2-isoprostanes
are formed by the free-radical-induced peroxidation of
arachidonic acid in cell membranes [4, 12]. This would
suggest that PH secondary to BPD does not generate
the oxidant stress seen in IPH at the molecular level
and/or that BPD enhances compensatory mechanisms to
scavenge free radicals. An alternative possibility would be
the preferential production of other isoprostane molecules
from arachidonic acid, such as E2 and D2 isoprostanes,
in children with BPD-associated PH. Polyunsaturated fatty
acids such as linoleic acid, DHA, and EPA may be oxidized
to form isoprostane like molecules more efficiently than
arachidonic acid [12]. Children with PH due to BPD may
have an unknown mechanism to encourage oxidation of
these polyunsaturated fats over arachidonic acid. This is
another potential explanation of the low F2-isoprostane
levels in children with BPD-associataed PH, although there
is no data on this possibility. Another alternative is inhibition
of F2-isoprostane formation by very high oxygen tension
with diversion to isofuran production; however, those with
BPD-associated PH in this study were not on significantly
higher FiO2 than the other groups [13]. In fact, all of the
groups were breathing a FiO2 of near 21%making hyperoxic
suppression of F2-isoprostanes very unlikely. The inevitable
pO2 difference between the pulmonary venous samples and
systemic venous samples did not appear to influence F2-
isoprostane levels as there was no difference in the F2-
isoprostane levels between the ASD controls, who all had
pulmonary venous samples, and the clinic controls, who all
had systemic venous samples. Regardless of any potential
mechanism to lower F2-isoprostane levels below normal
controls, this study strongly supports the absence of a high
level of uncompensated oxidant stress in this population of
children with PH secondary to BPD.
The limitations of this study include the fact that the
patients with PH due to BPD are younger and have a lower
BMI than both the controls and those with IPH. The age
difference is difficult to remedy as IPH typically presents later
in childhood while PH due to BPD is a disease of infants
and toddlers. If the patient survives infancy, PH secondary
to BPD tends to improve or even resolve with age leaving few
older children with active disease to study [2]. The lower BMI
in the PH due to BPD is likely a function of both the younger
age in this group and the commonly seen feature of failure
to thrive early in life in patients with BPD. The absence of
correlation of age or BMI with F2-isoprostane level suggests
the age and BMI differences do not explain the difference in
F2-isoprostanes seen in this study.
Another limitation of the study is the different PH sever-
ity among the IPH group and those with PH due to BPD. If
infants survive the initial malignant phase of PH secondary
to BPD, pulmonary artery pressures tend to decrease over
time [2]. This natural history of improvement in PH due to
BPD explains the lower pulmonary vascular resistance and
RVP/LVP in those with PH secondary to BPD compared to
those with IPH. The fact that no correlation exists between
hemodynamic measures of elevated pulmonary pressures
and F2-isoprostanes suggests the F2-isoprostane difference
between IPH and PH due to BPD is not caused by the
difference in PH severity. Similarly, analysis of only the
BPD PH patients with RVP/LVP >50% continues to show
significantly lower F2-isoprostanes than IPH patients and
controls. While clinical function data, such as New York
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Heart Association class, was not collected due to the difficulty
in applying these measures to infants and toddlers, normal
ventricular filling pressures, and normal cardiac outputs in
both groups demonstrate similar stable hemodynamic states
despite the difference in PH severity. A greater percentage of
those with IPH were on treatment with epoprostenol when
compared to those with PH due to BPD. Evidence exists that
this drug lowers F2-isoprostane levels in patients; thus, this
bias would act to lessen the difference between IPH patients
and the other 2 study groups [3]. Finally, it would be optimal
to increase the number of patients in the IPH group, but
the rarity of this disease in children makes obtaining larger
numbers difficult.
5. Conclusion
We found that pediatric patients with IPH have elevated
F2-isoprostane levels while children being followed for PH
secondary to BPD have low F2-isoprostane levels. This
marked difference in oxidant stress suggests each disease
has a unique pathophysiology. Future studies are needed
to better elucidate these differences thereby leading to
better targeted therapies for pediatric patients with a broad
spectrum of pulmonary hypertensive diseases.
Abbreviations
PH: Pulmonary hypertension
IPH: Idiopathic pulmonary hypertension
BPD: Bronchopulmonary dysplasia
ASD: Atrial septal defect
PVR: Pulmonary vascular resistance
WU: Woods units
IQR: Interquartile range
RVP/LVP: Right ventricular pressure as a
percentage of left ventricular pressure
RVEDP: Right ventricular end diastolic pressure
LVEDP: Left ventricular end diastolic pressure.
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